Home / PRF Papers / Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
In the phase 3b, randomized, double-blind, placebo-controlled DELIVER clinical trial, eptinezumab reduced migraine frequency and headache in adults with two to four prior preventive treatment failures. Here the effect of eptinezumab on coinciding patient-reported outcomes is reported.
